Here's the Prostate Cancer Research Institute weighing in:
PCRI Position On Task Force’s PSA Screening Recommendations
By Mark Scholz, MD; Executive Director
The U.S. Preventative Services Task Force recently concluded that the risks of PSA screening outweigh its benefits. The Task Force concedes that PSA screening may reduce cancer mortality, but that rampant overuse of surgery and radiation causes excessive harm to otherwise healthy men.
The Prostate Cancer Research Institute acknowledges the truth of these conclusions, specifically that PSA screening leads to unnecessary treatment. However, PCRI contends that PSA testing itself is not the culprit. Rather, it’s the rampant overuse of prostate biopsy.
For a biopsy to be safe, men must first receive further education, a policy that is not being followed at this time in the United States. Men need the opportunity to research their status further, possibly with additional imaging and urine tests, before taking the irreversible step of undergoing biopsy.
Rushing into biopsy frequently leads to an instant cancer diagnosis, frightening drastically unprepared patients into immediate and unnecessary surgery.
Dx Feb 2006, PSA 9 @age 43
RRP Apr 2006 - Gleason 3+4, T2c, NX MX, pos margins
PSA 5/06 <0.1, 8/06 0.2, 12/06 0.6, 1/07 0.7.
Salvage radiation (IMRT) Jan-Mar 2007
PSA 9/2007 and thereafter <0.1pcabefore50.blogspot.com